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Introduction: Hypofractionated stereotactic radiotherapy (HypoFXSRT)
has recently been used for the treatment of small lung tumors. We retro-
spectively analyzed the treatment outcome of HypoFXSRT for stage I
non-small cell lung cancer (NSCLC) treated in a Japanese multi-institu-
tional study.
Methods: This is a retrospective study to review 257 patients with
stage I NSCLC (median age, 74 years: 164 T1N0M0, 93 T2N0M0)
were treated with HypoFXSRT alone at 14 institutions. Stereotactic
three-dimensional treatment was performed using noncoplanar dy-
namic arcs or multiple static ports. A total dose of 18 to 75 Gy at the
isocenter was administered in one to 22 fractions. The median
calculated biological effective dose (BED) was 111 Gy (range,
57–180 Gy) based on /  10.
Results: During follow-up (median, 38 months), pulmonary com-
plications of above grade 2 arose in 14 patients (5.4%). Local
progression occurred in 36 patients (14.0%), and the local recur-
rence rate was 8.4% for a BED of 100 Gy or more compared with
42.9% for less than 100 Gy (p  0.001). The 5-year overall survival
rate of medically operable patients was 70.8% among those treated
with a BED of 100 Gy or more compared with 30.2% among those
treated with less than 100 Gy (p  0.05).
Conclusions: Although this is a retrospective study, HypoFXSRT
with a BED of less than 180 Gy was almost safe for stage I NSCLC,
and the local control and overall survival rates in 5 years with a BED
of 100 Gy or more were superior to the reported results for
conventional radiotherapy. For all treatment methods and schedules,
the local control and survival rates were better with a BED of 100
Gy or more compared with less than 100 Gy. HypoFXSRT is
feasible for curative treatment of patients with stage I NSCLC.
Key Words: Stereotactic radiotherapy, Non-small cell lung cancer,
Stage I, Hypofractionated.
(J Thorac Oncol. 2007;2: Suppl 3, S94–S100)
In Japan, due to the routine use of computed tomography(CT), detection of early-stage lung cancer is increasing. For
patients with stage I (T1 or 2, N0, M0) non-small cell lung
cancer (NSCLC), full lobar or greater surgical resection and
regional lymphadenectomy is the standard treatment choice;
the local control rates exceed 80% and the overall 5-year
survival rates surpass 50%.1 However, surgical resection is
often not feasible or involves a high risk for lung cancer
patients with tobacco-related pulmonary illnesses, severe car-
diovascular disease, or other medical conditions. Moreover, a
small proportion of the patients who are fit for surgery may
refuse it for personal reasons.
Radiotherapy (RT) can offer a therapeutic alternative in
these cases, but the outcome with conventional RT is unsat-
isfactory.2 The reason for the poor survival with conventional
RT is thought to be that the dose of conventional RT is too
low to control the local tumor. To give a higher dose to the
tumor without increasing the adverse effects, hypofraction-
ated high-dose stereotactic RT (HypoFXSRT) has recently
been used to treat small cell lung tumors, particularly in
Japan.3–6 Although the optimal treatment technique and
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schedule of HypoFXSRT for stage I NSCLC are unknown,
the nationwide number of Japanese patients with stage I
NSCLC who are treated with small-volume stereotactic RT
(SRT) has increased rapidly.
Therefore, it is meaningful to investigate the results of
SRT for stage I NSCLC from many institutions, even in a
retrospective manner, despite the large differences in treat-
ment protocols. Previously, we reported the result of a Jap-
anese multi-institutional review of 300 patients with stage I
NSCLC treated with SRT.7 We concluded that SRT with a
biological effective dose (BED) of less than 150 Gy is effective
for the curative treatment of patients with stage I NSCLC and
that the local control and survival rates are better with a BED of
100 Gy or more compared with less than 100 Gy.
The survival rates in selected medically operable pa-
tients with a BED of 100 Gy or more were promising and
potentially comparable with those of surgery. These results
for SRT were encouraging for stage I NSCLC patients;
however, the 300 subjects in that report included 17 patients
irradiated with comparatively small fractions (4 Gy) and 26
patients irradiated in combination with conventional RT. This
article presents the results for patients irradiated with Hy-
poFXSRT alone in a multi-institutional study. In this study,
we compared the reported results for surgery and conven-
tional RT with those for HypoFXSRT.
PATIENTS AND METHODS
Eligibility Criteria
This was a retrospective study to review patients who
were treated by HypoFXSRT for their stage I NSCLC in 14
different hospitals in Japan.
All the patients enrolled in this study satisfied the
following eligibility criteria: identification of T1N0M0 or
T2N0M0 primary lung cancer on chest and abdominal CT,
bronchoscopy, bone scintigraphy, or brain magnetic reso-
nance imaging; histological confirmation of NSCLC; perfor-
mance status of 2 or less according to the World Health
Organization (WHO) guidelines; and an inoperable tumor
due to a poor medical condition or refusal to undergo surgery.
No restrictions were imposed concerning the locations
of eligible tumors, irrespective of whether they were located
adjacent to a major bronchus, blood vessel, chest wall, or the
esophagus. Patients were informed of the concept, method-
ology, and rationale of this treatment, which was performed
in accordance with the 1983 revision of the Declaration of
Helsinki.
Patient Characteristics
The patient pretreatment characteristics are summa-
rized in Table 1. From April 1995 to March 2004, a total of
257 patients with primary NSCLC was treated using high-
dose HypoFXSRT in the following 14 institutions: Hokkaido
University, Kyoto University, Cancer Institute Hospital, To-
kyo Metropolitan Komagome Hospital, Kitasato University,
Tohoku University, Hiroshima University, Tokyo Metropol-
itan Hiroo Hospital, Sapporo Medical University, Institute of
Biomedical Research and Innovation, International Medical
Center of Japan, Tenri Hospital, Kitami Red Cross Hospital,
and University of Yamanashi. Of the 257 patients, 158 were
considered medically inoperable mainly because of chronic
pulmonary disease, advanced age, or other chronic illness.
The remaining 99 patients were considered medically oper-
able, but had refused surgery or had been advised to select
HypoFXSRT by medical oncologists.
Treatment Methods
All the patients were irradiated using stereotactic tech-
niques. For the purposes of this study, all the hypofraction-
ated stereotactic techniques met five requirements: reproduc-
ibility of the isocenter of 5 mm or less, as confirmed for every
fraction; slice thickness on CT of 3 mm or less for three-
dimensional (3-D) treatment planning; irradiation with mul-
tiple noncoplanar static ports or dynamic arcs; dose per
fraction size more than 4 Gy; and a total treatment period of
fewer than 25 days. Details of the techniques and instruments
used to achieve SRT in the 14 institutions were summarized
in a previous report.7 The clinical target volume (CTV)
marginally exceeded the gross target volume (GTV) by 0 to
5 mm. The planning target volume (PTV) comprised the
CTV, a 2- to 5-mm internal margin and a 0–5-mm safety
margin. A high dose was concentrated on the tumor-bearing
area, while sparing the surrounding normal lung tissues using
SRT. The irradiation schedules also differed among the
institutions. The number of fractions ranged between 1 and
14, with single doses of 4.4 to 35 Gy. A total dose of 30 to 84
Gy at the isocenter was administered with 6- or 4-MV x-rays
within 20% heterogeneity in the PTV dose. No chemotherapy
was administered before or during RT.
To compare the effects of various treatment protocols
with different fraction sizes and total doses, the BED was
used in a linear-quadratic model.8 Here, the BED was defined
as nd(1 d//), with gray units, where n is the fractionation
number, d is the daily dose, and / is assumed to be 10 for
tumors. The BED was not corrected with values for the tumor
doubling time or treatment term. In this study, the BED was
calculated at the isocenter. The median BED was 111.0 Gy
(range, 57.6–180.0). The BED was 100 Gy or more in 215
patients and less than 100 Gy in 42 patients. The median BED
for the less than 100 Gy and 100 Gy or more subgroups was
79.6 Gy (range, 57.6–98.6) and 117.0 Gy (range, 100.0–
180.0), respectively.
Dose constraints were set for the spinal cord only. The
BED limit for the spinal cord was 80 Gy (/ was assumed
to be 2 Gy for chronic spinal cord toxicity).
TABLE 1. Patient Pretreatment Characteristics
Total cases: 257
Age: 39–92 yr (median, 74)
Performance status: PS 0, 109; PS 1, 103; PS 2, 39; PS 3, 6
Pulmonary chronic disease: 168 positive, 89 negative
Histology: 111 squamous cell, 120 adenocarcinoma, 26 other
Stage: 164 IA, 93 IB
Tumor diameter: 7–58 mm (median, 28)
Medical operability: 158 inoperable, 99 operable
Journal of Thoracic Oncology • Vol. 2, No. 7, Supplement 3, July 2007 HypoFX Stereotactic Radiotherapy for Stage I NSCLC
Copyright © 2007 by the International Association for the Study of Lung Cancer S95
Evaluation
The objectives of this study were to retrospectively
evaluate the toxicity, local control rate, and survival rate
according to the BED. All patients underwent follow-up
examinations by radiation oncologists. The first examination
took place 4 weeks after treatment, and patients were subse-
quently seen every 1 to 3 months. Tumor response was
evaluated using the Response Evaluation Criteria in Solid
Tumors by CT.9 Chest CT (slice thickness, 2–5 mm) was
usually obtained every 3 months for the first year and re-
peated every 4 to 6 months thereafter. A complete response
(CR) indicated that the tumor had disappeared completely or
was replaced by fibrotic tissue. A partial response (PR) was
defined as a 30% or more reduction in the maximum cross-
sectional diameter. It was difficult to distinguish between
residual tumor tissue and radiation fibrosis. Any suspicious
confusing residual density after RT was considered evidence
of a PR, so the actual CR rate might have been higher than
that given here. Local recurrence was considered to have
taken place only when enlargement of the local tumor con-
tinued for more than 6 months on follow-up CT. Two radi-
ation oncologists interpreted the CT findings. The absence of
local recurrence was defined as locally controlled disease.
Lung, esophagus, bone marrow, and skin were evaluated
using version 2 of the National Cancer Institute–Common
Toxicity Criteria (NCI-CTC).
Statistical Analysis
The local recurrence rates in the two groups were
compared with the 2 test. The BED among patient groups at
each pulmonary toxicity grade was compared using the
Kruskal-Wallis test. The cumulative local control and sur-
vival curves were calculated and drawn applying the Kaplan-
Meier algorithms with day of treatment as the starting point.
Subgroups were compared using log-rank statistics. Values of
p  0.05 were considered statistically significant. Statistical
calculations were conducted using version 5.0 StatView soft-
ware (SAS Institute, Cary, NC).
RESULTS
All the patients completed the treatment with no par-
ticular complaints. The median duration of follow-up for all
patients was 38 months (range, 2–128).
Local Tumor Response
Of the 257 patients evaluated using CT, CR was
achieved in 66 (25.7%) and PR in 157 (61.1%). The overall
response rate (CR  PR) was 86.8%. The overall response
rates for tumors with a BED of 100 Gy or more (n  215) or
less than 100 Gy (n  42) were 87.5% and 86.7% in 3 years
(?), respectively. A typical case of a T1 tumor after Hypo-
FXSRT is shown in Figure 1.
Toxicity
Symptomatic radiation-induced pulmonary complica-
tions (NCI-CTC criteria grade 1) were noted in 28 patients
(10.9%). Pulmonary fibrosis or emphysema before treatment
was observed in 25 (89%) of the 28 patients with pulmonary
complications above grade 1. Pulmonary complications of
NCI-CTC criteria above grade 2 were noted in only 14
FIGURE 1. A typical example in-
volving SRT for a 76-year-old man
with T1N0 adenocarcinoma. He
was treated with HypoFXSRT. (A)
Before hypofractionated stereotactic
radiotherapy (HypoFXSRT). (B) The
calculated dose distribution. The
isocenter dose was 75 Gy/10 frac-
tions/5 days, and the tumor was
fully enclosed with the 90% dose
line. (C) Twelve months after Hy-
poFXSRT, a scarred tumor is rated
as a partial response.
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patients (5.4%). The pulmonary symptoms resolved in most
patients without steroid therapy, but six patients who had
very poor respiratory function or severe pulmonary fibrosis
before irradiation needed continuous oxygen. Chronic seg-
mental bronchitis and wall thickening causing atelectasis in
the peripheral lung was observed in one patient (0.4%).
Transient grade 3 esophagitis was observed in two patients
(0.8%) with tumors adjacent to the esophagus. Grade 3 or 4
dermatitis was observed in three patients (1.2%) with tumors
adjacent to the chest wall. Rib fracture adjacent to the tumor
was found in four patients (1.6%). No vascular, cardiac, or
bone marrow complications had been encountered as of the
last follow-up.
Recurrence
The recurrence rates of local, regional nodal, and dis-
tant lesions according to the BED and stage are listed in Table
2. The local recurrence rate was significantly lower for a BED
of 100 Gy or more compared with a BED of less than 100 Gy
(8.4 versus 42.9%, p 0.01). For greater BED subgroups, the
local recurrence rate was 11.8% for a BED of 120 Gy or more
(n  93) and 8.1% for a BED of 140 Gy or more (n  37).
The local recurrence rates for adenocarcinoma and squamous
cell carcinoma were 13.3% (16/120) and 17.1% (19/111),
respectively in 3 years. The cumulative local control rate
curves according to BED subgroup are shown in Figure 2.
The 5 (3? according to Table 2)-year local control rates of the
BED of 100 Gy or more and less than 100 Gy subgroups were
84.2% (95% confidence interval [CI]: 77.7%–90.8%) and
36.5% (95% CI: 10.4%–62.6%), respectively. According to
subgroup analysis, stage IB patients had a significantly higher
rate of local recurrence than stage IA patients. The nodal and
distant recurrence rates were almost identical in the stage IA
and IB subgroups.
In the patients with regional nodal recurrence, nodal
failures overlapped local failure in 3.1%, distant metastases in
3.9%, or both in 0.8% of the patients. Isolated local, nodal,
and distant recurrences were observed in 8.6%, 5.1%, and
13.6% of the patients, respectively.
Survival
The overall 3- and 5-year survival rates for all patients
were 56.8% (95% CI: 50.2%–63.5%) and 47.2% (95% CI:
38.7%–53.5%), respectively. The cause-specific 3- and
5-year survival rates were 76.9% (95% CI: 70.6%–83.2%)
and 73.2% (95% CI: 66.1%–80.2%), respectively. The over-
all survival rates differed significantly according to medical
operability, with intercurrent death in 36.8% of inoperable
patients and 10.3% of operable patients. The overall 5-year
survival rates of medically operable and inoperable patients
(Figure 3) were 64.8% (95% CI: 53.6%–75.9%) and 35.0%
(95% CI: 25.9%–44.1%), respectively. The overall survival
rates according to the BED in all patients differed signifi-
cantly between the BED of less than 100 Gy and 100 Gy or
more subgroups. The overall 5-year survival rates of the BED
100 Gy or more and less than 100 Gy subgroups were 53.9%
(95% CI: 46.0%–61.8%) and 19.7% (95% CI: 5.9%–33.4%),
respectively. For the subgroup of medically operable patients
with a BED of 100 Gy or more, the 3- and 5-year overall
survival rates were 80.4% (95% CI: 71.0%–89.7%) and
70.8% (95% CI: 59.3%–82.2%), respectively (Figure 2). The
overall 5-year survival rate according to stage in the operable
patients irradiated with a BED of 100 Gy or more was 72.3%
TABLE 2. Recurrence Rate According to the BED and Stage
Total cases BED <100 Gy BED >100 Gy p Stage IA Stage IB p
Local tumor 36/257 (14.0%) 18/42 (42.9%) 18/215 (8.4%) 0.01 20/164 (12.2%) 16/93 (17.2%) 0.21
Regional nodal metastasis 29/257 (11.3%) 9/42 (21.4%) 20/215 (9.3%) 0.05 17/164 (10.4%) 12/93 (12.9%) 0.54
Distant metastasis 51/257 (19.8%) 11/42 (26.2%) 40/215 (18.6%) 0.3 32/164 (19.5%) 19/93 (20.4%) 0.87
BED, biological effective dose.
FIGURE 2. Cumulative local control rate according to the
biological effective dose (BED). LC, local control rate; CI,
confidence interval.
FIGURE 3. Overall survival rate according to medical oper-
ability. OS, overall survival rate; CI, confidence interval.
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(95% CI: 59.1%–85.6%) for stage IA and 65.9% (95% CI:
43.0%–88.9%) for stage IB patients (Figure 4).
Reproducibility of the Data Among Institutions
Table 3 compares the irradiation method and results for
three major institutions enrolled in this study. These institu-
tions used a BED of 100 Gy or more. The local control and
3-year survival rates were almost identical.
DISCUSSION
At present, surgery is the standard treatment for stage I
NSCLC. RT is offered to patients who are unsuitable for
surgery because of medical problems and to patients who
refuse surgery. Most information on the results of RT for
stage I NSCLC is based on retrospective studies of RT-
treated inoperable NSCLC cases. Therefore, the role of RT
for stage I NSCLC, as a curative modality, has not yet been
established.
Qiao et al. summarized 18 papers on stage I NSCLC
treated with conventional RT alone published between 1988
and 2000.10 Local recurrence was the most common rea-
son for treatment failure of stage I NSCLC with conventional
RT, but the frequency of recurrence varied considerably
according the report (between 6.4% and 70%). The 3-year
recurrence rate was approximately 60%,11–13 with a median
time to relapse that ranged from 21 to 30 months.12,14,15
Generally, smaller tumor size, low T stage, and increased
dose had a favorable impact on local control, and increased
local control was followed by increased survival.14,16 How-
ever, the overall treatment results were disappointing. The
median survival in these studies ranged from 18 to 33
months. The 3- and 5-year overall survival rates were 34 
9% and 21  8% (mean  1 SE), respectively. The cause-
specific survival rates at 3 and 5 years were 39  10% and
25  9% (mean  1 SE), respectively. Regarding treatment
toxicity, severe (grade 3 or above) radiation esophagitis14 and
pneumonitis11 occurred in 4.1% and 6.1% of the cases,
respectively. Better local control may be achieved when the
total dose is increased,15,16 and a trend has been growing
toward seeking better local control by increasing the
BED13–15 for a relatively limited span of doses (BED 59–76
Gy). Dose escalation has been the focus of developmental
therapeutic strategies for inoperable stage I NSCLC to im-
prove local control and survival.
Mehta et al.17 provided a detailed theoretical analysis
regarding the responses of NSCLC to RT and a rationale for
dose escalation. They concluded that a greater BED irradiated
during a short period must be given to gain local control of
lung cancers. Giving a higher dose to the tumor without
increasing the adverse effects was shown to be possible using
the SRT technique; this is now feasible due to the technolog-
ical progress that allows increasing the accuracy of localiza-
tion to the tumor-bearing area using various imaging tools.
SRT can also reduce the overall treatment time substantially,
from several weeks for conventional RT to a few days,
offering an important advantage to the patient.
After Uematsu et al.18 reported a landmark study on
SRT for stage I NSCLC using a CT-linac system, SRT has
been actively investigated for stage I NSCLC in Japan and the
United States. In the reports listed in Table 4,3–6,19–21 the
local control rates of primary lung cancer with SRT ranged
from 87% to 97% when the BED exceeded 100 Gy. Uematsu
et al.3 showed excellent survival rates for medically operable
patients, approximating those for full lobar surgical resection;
however, they studied only a few patients, and it is not known
whether the result is reproducible. Table 5 compares the
results of Uematsu et al.3 with the HypoFXSRT results
presented here. These results suggest that the local control
and survival rates of HypoFXSRT for stage I NSCLC are
promising and reproducible when the BED exceeds 100 Gy.
In Japan, we consider a BED greater than 100 Gy to be
a satisfactory dose for HypoFXSRT of stage I NSCLC, with
a local control rate better than 85%, and a further dose
escalation study is not necessary for tumors smaller than 4 cm
in diameter. Conversely, in the United States, Timmerman et
al.22 concluded that 60 Gy in three fractions (BED 180 Gy)
is the proper dose, and they adopted this dose and fraction
protocol for their prospective study. We need to observe the
FIGURE 4. Overall survival rate in operable patients accord-
ing to the biological effective dose (BED). OS, overall survival
rate; CI, confidence interval.
TABLE 3. Comparison of the Irradiation Methods and Results for Three Major Institutions
Institution
No. of
Patients
Total Isocenter
Dose (Gy)
Single Isocenter
Dose (Gy) BED (Gy)
Median Follow-up
(mo) Local Failure, %
5-yr Overall
Survival, %
Kyoto 42 48 12 106 40 3 64
Cancer Institute 30 50–62.5 10–12.5 100–141 25 4 77
Kitami 27 50–60 7.5–10 100–105 71 4 63
BED, biologically effective dose (/  10) recalculated at the isocenter.
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results of ongoing phase II studies on SRT for stage I NSCLC
conducted in Japan (12 Gy  4  48 Gy prescribed to the
isocenter) and the United States (20 Gy  3  60 Gy
prescribed to cover 95% of the PTV).
The 5-year overall survival rate for medically operable
patients with HypoFXSRT is encouraging (Table 6). Repre-
sentative 5-year overall survival rates for clinical stage IA
and IB with surgery range from 61% to 72% and 40% to
50%, respectively.23–25 According to our data, the survival
rate for SRT was not worse than that for large surgical series.
Furthermore, concerning toxicity, approximately 3% of pa-
tients died as a result of surgery, and chronic morbidity
occurs in 10% to 15% of patients after surgery.26 Hypo-
FXSRT is much less invasive than surgery, and it is postu-
lated that SRT will become a major treatment choice for stage
I NSCLC, at least for medically inoperable patients.
Multi-institutional phase II studies of SRT for stage I
NSCLC have been started in Japan (JCOG0403)27 and the
United States (RTOG0236).28 However, it will take several
years to obtain conclusive results, and an inevitable selection
bias exists in comparing SRT with surgical series for patients
in retrospective or phase II studies.
Although the differences in techniques and schedules of
the institutions enrolled in this study may be large, it is
meaningful that a safe, effective BED was suggested because
the optimal dose-fraction schedule of SRT for stage I NSCLC
is not known. Furthermore, this is the only report that gives
the results of SRT for a large number of medically operable
stage I NSCLC patients. Based on our excellent SRT results,
it is arguable that a phase III study comparing surgery and
SRT for medically operable patients is warranted. However,
it is very difficult to perform a phase III study because most
patients will opt for less invasive therapy such as SRT. We
need much more experience and must study more patients
with a longer follow-up duration to establish a safe, effective
irradiation method that will instill both medical and social
confidence in SRT for treatment of stage I NSCLC.
When we compare the results of conventional RT and
surgery with those of HypoFXSRT, we conclude that
HypoFXSRT has the following benefits for stage I NSCLC.
First, HypoFXSRT is a safe and promising treatment modal-
ity. Second, the local control and survival rates are superior to
those of conventional RT. Third, HypoFXSRT should be a
standard of care for medically inoperable patients. Fourth,
HypoFXSRT should be randomly compared with surgery for
medically operable patients. Finally, we need additional ex-
perience with a longer follow-up duration to conclusively
validate these points.
TABLE 5. Comparison of the Results between the
Multi-institutional Study and the Uematsu et al. Study
Uematsu et al. 3 Multi-institutional
Total no. of cases 50 215
T1N0M0 24 141
T2N0M0 26 75
Follow-up duration, mo (median) 22–66 (36) 2–128 (38)
Local control, % 94 90
Regional lymph nodes
metastases, %
4 7
Distant metastases, % 14 19
Grade 3 toxicity, % 0 3
3-yr overall survival rate, % 66 64
3-yr cause-specific survival
rate, %
88 83
5-yr overall survival rate, % 55 55
5-yr cause-specific survival
rate, %
81 77
3-yr overall survival rate in
operable patients, %
86 82
5-yr overall survival rate in
operable patients, %
77 72
TABLE 6. Comparison of 5-Year Overall Survival Rate
between Stereotactic Radiotherapy and Surgery
Stage Author
Mountain23* Naruke et al.24* Shirakusa and Koybayashi25* Onishi†
IA 61% 71% 72% 72%
IB 40% 44% 50% 66%
*Surgery.
†HypoFXSRT presented here.
TABLE 4. Reports of Stereotactic Radiotherapy for Stage I Non-small Cell Lung Cancer
Author (ref.)
No. of
Patients
Total
Dose* (Gy)
Single
Dose* (Gy) BED† (Gy)
Median
Follow-up (mo)
Local
Progression, %
3-yr Overall
Survival, %
Uematsu et al.3 50 72 7.2 124 60 6 66
Nagata et al.4 42 48 12 106 52 3 82
Fukumoto et al.5 17 48–60 6–7.5 99–137 24 6 NA
Onishi et al.6 28 72 7.2 124 24 8 75
Hof et al.19 10 19–26 19–26 55–94 15 20 NA
McGarry et al.20 47 75 25 263 15 13 NA
Wulf et al.21 12 26–57 19–26 94–165 11 5% NA
BED, biologically effective dose; NA, not assessed.
*Stereotactic radiotherapy dose is calculated at the isocenter.
†BED (/  10) recalculated at the isocenter.
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